Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Short Interest Update

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) was the target of a large growth in short interest in June. As of June 30th, there was short interest totaling 7,748 shares, a growth of 94.0% from the June 15th total of 3,994 shares. Based on an average daily volume of 35,104 shares, the days-to-cover ratio is currently 0.2 days. Currently, 1.5% of the company’s shares are sold short.

Eloxx Pharmaceuticals Price Performance

Shares of NASDAQ ELOX opened at $12.00 on Friday. Eloxx Pharmaceuticals has a 1 year low of $11.13 and a 1 year high of $17.50. The company’s 50-day moving average is $17.53. The stock has a market capitalization of $8.26 million, a PE ratio of -0.78 and a beta of -1,891.27.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.